Oligodendroglioma: A Review of Management and Pathways

Simple item page
dc.contributor.authorZerdan, Maroun Bou
dc.contributor.authorAssi, Hazem I.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentDivision of Hematology Oncology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:01:57Z
dc.date.available2025-01-24T12:01:57Z
dc.date.issued2021
dc.description.abstractAnaplastic oligodendrogliomas are a type of glioma that occurs primarily in adults but are also found in children. These tumors are genetically defined according to the mutations they harbor. Grade II and grade III tumors can be differentiated most of the times by the presence of anaplastic features. The earliest regimen used for the treatment of these tumors was procarbazine, lomustine, and vincristine. The treatment modalities have shifted over time, and recent studies are considering immunotherapy as an option as well. This review assesses the latest management modalities along with the pathways involved in the pathogenesis of this malignancies. © Copyright © 2021 Bou Zerdan and Assi.
dc.identifier.doihttps://doi.org/10.3389/fnmol.2021.722396
dc.identifier.eid2-s2.0-85117308050
dc.identifier.urihttp://hdl.handle.net/10938/31471
dc.language.isoen
dc.publisherFrontiers Media S.A.
dc.relation.ispartofFrontiers in Molecular Neuroscience
dc.sourceScopus
dc.subjectAnaplastic oligodendroglioma
dc.subjectIdh mutation
dc.subjectLomustine
dc.subjectPcv
dc.subjectProcarbazine
dc.subjectTemozolomide
dc.subjectVincristine
dc.subjectCyclin dependent kinase inhibitor 2a
dc.subjectIsocitrate dehydrogenase 1
dc.subjectIsocitrate dehydrogenase 2
dc.subjectNotch1 receptor
dc.subjectPlatelet derived growth factor
dc.subjectTelomerase reverse transcriptase
dc.subjectCancer chemotherapy
dc.subjectCancer grading
dc.subjectCancer growth
dc.subjectCancer immunotherapy
dc.subjectCarcinogenesis
dc.subjectChromosome 1p
dc.subjectChromosome 9p
dc.subjectChromosome deletion
dc.subjectCic gene
dc.subjectFubp1 gene
dc.subjectGene
dc.subjectGene mutation
dc.subjectGlioma
dc.subjectHuman
dc.subjectOligodendroglioma
dc.subjectPhase 1 clinical trial (topic)
dc.subjectPhase 2 clinical trial (topic)
dc.subjectPhase 3 clinical trial (topic)
dc.subjectPhase 4 clinical trial (topic)
dc.subjectProtein expression
dc.subjectRandomized controlled trial (topic)
dc.subjectReview
dc.subjectSignal transduction
dc.titleOligodendroglioma: A Review of Management and Pathways
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2021-5838.pdf
Size:
301.13 KB
Format:
Adobe Portable Document Format
Download

Collections

Internal Medicine